Arcus Biosciences (RCUS) is down -11.2%, or -$2.81 to $22.33.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences Stock (RCUS) Collapses 17% after Failed Stomach Cancer Study
- Arcus Biosciences Ends Phase 3 STAR-221 Study
- Arcus Biosciences announces discontinuation of STAR-221 study
- Arcus Biosciences price target raised to $26 from $17 at BofA
- Arcus Biosciences Completes Successful Stock Offering